ibuprofen
Enable an agent to recognise ibuprofen, assess the identity and condition of a material containing it, and determine which handling or use decisions require further evidence.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an agent to recognise ibuprofen, assess the identity and condition of a material containing it, and determine which handling or use decisions require further evidence.
Ibuprofen is a synthetic chiral arylpropionic acid nonsteroidal anti-inflammatory drug that reduces pain, fever and inflammation through reversible inhibition of cyclooxygenase-mediated prostaglandin synthesis.
It can be Compare a declared ibuprofen identity with analytical and supplier evidence, flagging unresolved chemical-form or stereochemical differences.; Normalise ibuprofen content only when the chemical form, equivalence basis and units are known.; Assess a batch against an explicitly identified specification and route unresolved results for review.; Select handling and storage actions from documentation applicable to the actual material or formulation.; Link an ibuprofen-containing medicine to its product information before interpreting release, administration or clinical restrictions..
Distinguishing features
Chemical identity must match ibuprofen's molecular structure; an analgesic indication, trade name or tablet appearance does not establish identity.
Distinguish racemic ibuprofen from a single-enantiomer material using explicit stereochemical designation and, where required, analytical evidence.
Distinguish the free acid from an ibuprofen salt by the declared chemical form and counterion rather than treating their masses as interchangeable.
Distinguish bulk ibuprofen active ingredient from a finished medicine containing ibuprofen, excipients and possibly additional active ingredients.
Distinguish ibuprofen from other anti-inflammatory medicines through substance-specific identity evidence rather than shared therapeutic classification.
Scope
+ Chemical identity and evidence distinguishing ibuprofen from other active ingredients
+ Stereochemical composition and relationships between racemic ibuprofen, individual enantiomers and salt forms
+ Physical form, solubility behaviour and material condition
+ Assay, impurities, degradation and batch-specific quality evidence
+ Relationships between ibuprofen content, formulation, release behaviour and intended pharmaceutical function
- Complete branded medicine records, packaging configurations and marketing authorisations
- Patient-specific prescribing, dosing, contraindication assessment or treatment recommendations
- Full models of related substances such as dexibuprofen, ibuprofen salts or metabolites
- Manufacturing equipment, synthesis operations and facility qualification
- Disease models and clinical care pathways
- Complete environmental fate and wastewater treatment models
Characteristics
- Chemical identity
- Structure identifier and chemical name, with the identifier's stereochemical and salt-form scope stated Prevents a product label or therapeutic category from substituting for substance identification.
- Stereochemical composition
- R and S proportions in %, with analytical method; unknown where unmeasured Separates racemic material from enantiomer-enriched material and supports correct links to neighbouring substance models.
- Chemical form
- Free acid, named salt or unresolved form; hydration or solvation specified where relevant Controls the interpretation of identity, mass, composition and formulation evidence.
- Ibuprofen content
- % mass fraction, mg/g, mg/mL or mg per dosage unit, with free-acid-equivalent and dry/as-is basis stated Makes content comparable without confusing total formulation mass with ibuprofen mass.
- Solid-state and particle condition
- Observed solid form and aggregation state; particle-size distribution in µm where relevant Supports investigation of differences in processing and dissolution.
- Solubility under specified conditions
- mg/mL or mol/L, with solvent, pH, temperature and method Avoids treating a condition-dependent property as a single universal value.
- Impurity and degradation profile
- Named components in %, ppm or a method-specific reporting basis, with detection limits Allows quality decisions to rest on measured composition and applicable limits.
- Quality disposition
- Unassessed, quarantined, released, rejected or retest required, with authority and evidence Separates verified suitability from mere possession or apparent identity.
- Formulation relationship
- Linked medicinal product, ingredient role, declared strength and release designation Connects the substance to its presentation while keeping product behaviour outside substance identity.
Also called
Where this came from
wikidata · CC0 1.0
Also registered as vr.tr.ibuprofen
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 5 bundles · 9 layers · 17 findings · 25 questions.
Ibuprofen identity and boundaries Establishes which chemical entity is being described and separates it from related substances and products.
The name ibuprofen alone does not resolve stereochemistry, salt form or whether the subject is an ingredient or a medicine.
Molecular and stereochemical identity
Records the identity claims and evidence needed to recognise ibuprofen.
Identity evidence to establish
The draft requires a verified structural identity and an explicit account of stereochemical composition.
- Which authoritative structure and identifiers define ibuprofen here, and do they explicitly represent a racemate or leave stereochemistry unspecified? definition
- Which analytical evidence establishes chemical identity, and which additional evidence establishes the R/S composition? measurement
Related forms and products
Locates salts, enantiomers and finished medicines relative to this registry entry.
Chemical form and product boundary
Related forms and formulations need explicit relationships rather than silent identity equivalence.
- How should this entry link to dexibuprofen and named ibuprofen salts without duplicating their substance models? boundary
- Is the material under assessment bulk free-acid ibuprofen, a related chemical form or a finished medicine containing it? definition
Physical form and formulation behaviour Captures material properties that affect how ibuprofen can be processed, dispersed or released.
Chemical identity alone cannot explain the behaviour of different ibuprofen materials and preparations.
Solid material characterisation
Examines the physical attributes of the actual ibuprofen material.
Solid-state and particle evidence
Solid form and particle measurements should be recorded where they affect the intended application.
- What solid-state characterisation supports the form assigned to this ibuprofen sample? measurement
- Which particle-size, aggregation or moisture attributes must be controlled for its intended formulation process? action
Solution and release conditions
Separates substance solubility evidence from formulation-specific dissolution and release.
Condition-specific solubility and dissolution
Solubility and dissolution records need conditions and a clear distinction between ingredient and product results.
- What ibuprofen solubility has been measured at the relevant pH, temperature and solvent composition? measurement
- Which observed release properties belong to the ibuprofen material, and which require the linked formulation model? boundary
Ibuprofen quality and stability Connects content, impurities and storage history to evidence-based material disposition.
A material may be correctly identified as ibuprofen while remaining unsuitable for its intended use.
Assay and related substances
Defines the evidence needed to interpret ibuprofen content and unwanted components.
Specification-linked composition
Assay and impurity results require an applicable specification, method and reporting basis.
- Which pharmacopoeial or other authorised specification and edition apply to this ibuprofen material and intended use? provenance
- What assay and related-substance results are available, and on what chemical-form and moisture basis are they reported? measurement
Storage and material disposition
Relates documented storage conditions and stability evidence to continued suitability.
Stability-supported disposition
Retest, release or rejection decisions should use evidence specific to the material and its storage history.
- What stability evidence supports the assigned storage conditions, container and retest or expiry date for this material? provenance
- Which storage excursions or analytical changes require quarantine, retesting or rejection under the applicable procedure? action
Pharmaceutical role and action limits Links ibuprofen's pharmaceutical role to product evidence and appropriate decision boundaries.
An agent must distinguish recognising an active ingredient from establishing that a particular medicine or use is appropriate.
Active ingredient role
Connects substance-level pharmacological evidence with the medicinal products that contain ibuprofen.
Pharmacology and product linkage
Pharmacological claims require sources, while indications and administration details require a specific product context.
- Which authoritative sources establish ibuprofen's pharmacological class and mechanism, including any relevant stereochemical distinctions? provenance
- Which indications, routes and release claims belong to the linked authorised product rather than to ibuprofen in isolation? boundary
Handling and clinical handoff
Identifies the documentation needed for material handling and for referral to clinical decision models.
Evidence required before action
Handling bulk material and administering a medicine require different evidence and decision contexts.
- Which safety data sheet and local procedures govern handling, spills and disposal of this particular ibuprofen material? action
- What product and patient information must be handed to a clinical decision model before assessing administration, interactions or restrictions? boundary
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This describes the active chemical substance from recall; no sources were consulted.
- Physical-property values refer to the free acid and depend on stereochemical composition and measurement conditions.
- Researchers should verify current pharmacopoeial editions and jurisdiction-specific product approvals, restrictions and safety wording.
- Which of these check these first hold for the sense of ibuprofen this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Racemic ibuprofen
- Dexibuprofen, the isolated S-enantiomer
- Ibuprofen sodium
- Ibuprofen lysine
- Which of these kinds and varieties hold for the sense of ibuprofen this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- CAS Registry Number - 15687-27-1 - Identifies ibuprofen; individual enantiomers and salts have separate identifiers.
- WHO Anatomical Therapeutic Chemical classification - M01AE01 - Ibuprofen within propionic acid derivative anti-inflammatory and antirheumatic products.
- IUPAC chemical nomenclature - 2-[4-(2-methylpropyl)phenyl]propanoic acid - Names the molecular constitution without specifying an enantiomer.
- Which of these identifiers and schemes hold for the sense of ibuprofen this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- United States Pharmacopeia-National Formulary, issued by USP: monographs establish quality requirements for ibuprofen drug substance and specified preparations.
- European Pharmacopoeia, published by the Council of Europe's EDQM: its ibuprofen monograph establishes pharmaceutical quality requirements.
- Which of these standards and regulation hold for the sense of ibuprofen this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Symptomatic relief of mild to moderate pain.
- Reduction of fever.
- Relief of primary dysmenorrhoea.
- Symptomatic treatment of inflammatory musculoskeletal and arthritic conditions.
- Certain intravenous ibuprofen products are used to close a patent ductus arteriosus in premature infants.
- Which of these real-world use hold for the sense of ibuprofen this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Molar mass of the free acid - 206.28 - g/mol
- Melting range of racemic free acid - 75-78 - °C
- Acid dissociation constant, pKa - Approximately 4.9 - dimensionless
- Which of these typical measurements hold for the sense of ibuprofen this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Gastrointestinal ulceration, bleeding and perforation.
- Kidney injury and fluid retention, particularly with dehydration or impaired kidney function.
- Increased risk of cardiovascular thrombotic events, including myocardial infarction and stroke.
- Hypersensitivity reactions, including bronchospasm in susceptible people and rare severe skin reactions.
- Use during pregnancy can cause fetal kidney dysfunction and premature closure of the fetal ductus arteriosus.
- Which of these failure modes and hazards hold for the sense of ibuprofen this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Nonprescription availability, permitted strengths, pack sizes and age restrictions differ between jurisdictions.
- Availability and approved indications of topical, intravenous, salt and single-enantiomer products vary by country.
- Which of these regional variation hold for the sense of ibuprofen this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Dexibuprofen - The isolated S-enantiomer; conventional ibuprofen is generally supplied as a racemic mixture.
- Naproxen - A distinct propionic acid derivative NSAID with a different molecular structure and generally longer elimination half-life.
- Aspirin - A salicylate that irreversibly acetylates cyclooxygenase; ibuprofen inhibits it reversibly.
- Paracetamol - An analgesic and antipyretic with little clinically useful peripheral anti-inflammatory activity.
- Ibuprofen medicinal product - A formulated preparation containing ibuprofen plus excipients; the registered substance is distinct from a brand, dosage form or individual tablet.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of ibuprofen this model covers, and on what evidence? provenance
What the second pass must settle
- Does the registry intend ibuprofen to denote the racemic free acid specifically, and are existing models already authoritative for that identity or its related forms?
- Which authoritative identity sources and current quality specifications should anchor the researched model?
- Which solid-state and particle attributes are demonstrably significant for the ibuprofen materials covered, rather than merely possible measurements?
- What evidence supports storage limits, degradation markers and retest decisions for bulk ibuprofen versus individual formulations?
- Which pharmacological findings can be stated at substance level, and which safety or use claims must remain attached to a jurisdiction-specific medicinal product?